



Gene Comprehensive Nutrigenomic Report

Accession Number: #####

Report Generated: December 13, 2018

Specimen Received: ##/##/####

Created For: #####

DOB: ##/##/####

Male



Do not make any decisions about your health solely based on the information contained in this report.
Always consult with a licensed and experienced health practitioner when you receive this report.

– 34 – Male

(-/-) No clinical abnormality

(+/-) Heterozygous result

(+/-) Heterozygous result

rsID	Gene	Genetic Result	Therapeutics Associated With Positive Result	Highly Recommended Therapeutics / Neurobiologix Formulas	Provider Discretion: As Needed Formula Recommendations	Lifestyle Recommendations	Laboratory Recommendations
Chronic Pain							
Inflammation Control							
rs10402876	C3	+/-	Anti-Inflammatory Therapy: Curcumin, Omega 3s, Resveratrol, Quercetin, Low Dose Naltrexone (LDN), CBD Oil	CBD Oil, PEA Soothe Support™, Prescription Low Dose Naltrexone (LDN)		Consider Low Inflammatory Diet	Consider Pregnenolone, Cortisol, Progesterone, Testosterone, T cell profile, Sed Rate, ANA, C Reactive Protein, Routine Thyroid Panel, Candida Titer, EBV Titer, Food Allergy Panel, Environmental Allergy Testing
rs2569191	CD14	+/-					
rs1143634	IL1B	-/-					
rs1800795	IL6	+/+					
rs2069812	IL5	+/-					
rs1800925	IL13	-/-					
rs10181656	STAT4	+/+					
rs1800629	TNF	-/-					
rs361525	TNF	-/-					
rs231775	CTLA4	+/-					
rs1076560	DRD2	-/-	Increased Efficacy of Naltrexone				

– 34 – Male

(-/-) No clinical abnormality

(+/-) Heterozygous result

(+/+) Homozygous result

rsID	Gene	Genetic Result	Therapeutics Associated With Positive Result	Highly Recommended Therapeutics / Neurobiologix Formulas	Provider Discretion: As Needed Formula Recommendations	Lifestyle Recommendations	Laboratory Recommendations
Chronic Pain							
Chemical Detoxification							
rs1021737	CTH	-/-	N-Acetyl Cysteine (NAC), Glutathione				
rs819147	AHCY	-/-					
rs1056806	GSTM1	-/-	Glutathione		IV Glutathione Glutathione Suppositories Glutathione Ultra™ Glutathione Plus Topical™	Consider IV Glutathione Treatment and Pre-Anesthesia Glutathione Treatment Herbicide and Pesticide Avoidance	
rs7483	GSTM3	+/-					
rs1695	GSTP1 I105V	-/-					
rs1138272	GSTP A114V	-/-					
Neurotransmitters / Pain Control							
rs4680	COMT V158M	+/+	Taurine, Choline, TMG, DMG, Methionine, SAME, Inositol	Full Focus, Advanced Neurotransmitter Support			Consider Neurotransmitter Testing and PGX
rs4633	COMT H62H	+/+					
rs769407	GAD1	+/-	Prescription Amantadine, Ketamine, Glycine, N-Acetyl-Cysteine (NAC), Beta Phenyl GABA, Zinc, Magnesium, Oxaloacetate, Elderberry, L-Theanine, Melatonin	Pro GAD Enhancer™ Prescription Amantadine Calming Cream			Consider Neurotransmitter Testing Consider PGx Testing
rs3828275	GAD1	+/-					
rs1799971	OPRM1 A118G	+/+	Defines Sensitivity To Opiates			Expect lower than normal response to opiate medications. Will most likely need higher dose or stronger opiate for adequate pain control	Consider PGx Testing
rs1045642	ABCB1 C3435T	-/-					

Summary for Chronic Pain

Highly Recommended Therapeutics / Neurobiologix Formulas

- **CBD Oil, PEA Soothe Support™, Prescription Low Dose Naltrexone (LDN)**
- **Full Focus, Advanced Neurotransmitter Support**
- Pro GAD Enhancer™**
- **Prescription Amantadine**
- Calming Cream**

Lifestyle Recommendations

- Consider Low Inflammatory Diet
- Consider IV Glutathione Treatment and Pre-Anesthesia Glutathione Treatment
- Herbicide and Pesticide Avoidance
- Expect lower than normal response to opiate medications. Will most likely need higher dose or stronger opiate for adequate pain control

Laboratory Recommendations

- Consider Pregnenolone, Cortisol, Progesterone, Testosterone, T cell profile, Sed Rate, ANA, C Reactive Protein, Routine Thyroid Panel, Candida Titer, EBV Titer, Food Allergy Panel, Environmental Allergy Testing
- Consider Neurotransmitter Testing and PGX
 - Consider Neurotransmitter Testing
 - Consider PGx Testing
 - Consider PGx Testing

Gene Information Key

rsID	Gene	"-" variant	"+" variant
rs1045642	ABCB1 C3435T	G	A
rs819147	AHCY	T	C
rs10402876	C3	G	C
rs2569191	CD14	T	C
rs4633	COMT H62H	C	T
rs4680	COMT V158M	G	A
rs1021737	CTH	G	T
rs231775	CTLA4	A	G
rs1076560	DRD2	C	A
rs769407	GAD1	G	C
rs3828275	GAD1	C	T
rs1056806	GSTM1	C	T
rs7483	GSTM3	C	T
rs1695	GSTP1:I105V	A	G
rs1138272	GSTP:A114V	C	T
rs1800925	IL13	C	T
rs1143634	IL1B	G	A
rs2069812	IL5	A	G
rs1800795	IL6	G	C
rs1799971	OPRM1 A118G	A	G
rs10181656	STAT4	C	G
rs361525	TNF	G	A
rs1800629	TNF	G	A

Definitions

DETOXIFICATION	Detoxification enzymes are responsible for clearing environmental chemicals and metabolites from our body. Accumulation of these chemicals and by-products can damage intracellular biochemical functions. Alterations in these systems can have a significant negative effect on the nervous system and immune systems functions. These polymorphisms can result in decreased "quality of life" and even decreased "life-span".
AHCY	Adenosylhomocysteinase (AHCY) is an enzyme that breaks down S-adenosylhomocysteine (SAH) to homocysteine and adenosine. Polymorphisms in this gene will lead to lower levels of homocysteine and glutathione.
CTH	Glutathione production is dependent on the function of the enzyme cystathionine gamma-lyase (CTH). CTH converts cystathionine to cysteine. Individuals with mutations in the CTH gene are predicted to have decreased glutathione-mediated detoxification.
GSTM1	Glutathione S-transferase M1 (GSTM1) is an important enzyme in the body's detoxification pathway. GSTM1 conjugates glutathione to molecules (drugs, environmental toxins, carcinogens etc.) bound for excretion. GSTM1 is mainly responsible for binding toxins in joints and for binding carcinogens.
GSTM3	Glutathione S-transferase mu 3 is an enzyme that detoxifies drugs, environmental toxins, and carcinogens by conjugating toxins to glutathione and subsequent excretion by the kidneys. Mutations in GSTM3 are associated with decreased clearance of toxins, anesthetics and drugs from the nervous system.
GSTP1	Glutathione S-transferases (GSTs) are a family of enzymes that play an important role in detoxification. The glutathione S-transferase pi gene (GSTP1) functions in chemical clearance and anti-inflammatory properties. High concentration of GST-p are found in the skin, lungs, sinuses, bladder and the intestinal tract. Polymorphisms of this enzyme allow for increased inflammatory activity in these areas that include eczema, asthma, chronic sinusitis, IBS, "leaky" gut and interstitial cystitis.
DEVELOPMENTAL	
ABCB1:C3435T	The ABCB1 gene encodes the multidrug resistance (MDR) protein, a membrane pump that effluxes drugs from the cytoplasm to the extracellular fluid. MDR is enormously important in formation of brain and gut barriers, drug and nutrient excretion, and normal development. Mutations in the ABCB1 gene are associated with a host of perturbations in an individual's response to drugs and nutrients.
INFLAMMATORY	
This enzyme category has significant effects on the inflammatory state of a person's body. Polymorphisms in these specific enzymes will significantly increase the levels of inflammation in the body. By supplementing these enzyme deficiencies, the patient will effectively reduce inflammatory damage to the body.	
C3	Essential for the immune response, C3 is a protein involved in initiation of the complement system. C3 polymorphisms are associated with susceptibility to asthma and other inflammatory disorders.
CD14	The CD14 protein is a macrophage cell surface receptor that binds bacterial cell wall components. As one of the initiators of the innate immune response, fully functional CD14 is necessary for normal response to potential pathogens. Mutations in the CD14 gene are associated with susceptibility to asthma and other allergen-mediated inflammatory processes.
CTLA4	Cytotoxic T-lymphocyte Associated protein 4 (CTLA4) is an important inhibitor of T-cell activity: CTLA4 is part of the signaling cascade that turns off overactive T cells. Mutations in the gene that encodes CTLA4 are associated with a host of diseases characterized by a heightened immune state.
DRD2	Dopamine receptor D2 is an important component of the neuroinflammation process. Activation of DRD2 signaling is thought to decrease TNFalpha release from inflammatory mast cells. Polymorphisms associated with decreased DRD2 signaling activity are predicted to lead to pro-inflammatory phenotypes.
IL13	IL13 (Interleukin 13) is a member of the interleukin family of chemical messengers of the immune system. Polymorphisms in this gene are associated with changes in IL13 gene expression and increase the risk of more severe inflammatory responses to allergens.
IL5	The protein product of the Interleukin 5 gene (IL5) is important for normal development of B lymphocytes and eosinophils (a pro-inflammatory white blood cell). Inactivating mutations in the IL5 gene are associated with susceptibility to certain viral infections and increased aggression of inflammatory response. These polymorphisms are also associated with increased aggression of allergies, asthma and eosinophilia.
IL6	Interleukin 6, IL6, is an important pro-inflammatory cytokine. Polymorphisms in this gene leads to a more aggressive inflammatory response. Patients with IL-6 mutations require assistance with inflammatory control.
STAT4	The Signal Transducer and Activator of Transcription 4 (STAT4) gene encodes a transcription factor that responds to extracellular growth factors and cytokines. Mutations in the STAT4 gene are associated with inflammatory disorders like lupus and rheumatoid arthritis.
TNF	Tumor necrosis factor, TNF, is an important pro-inflammatory signaling molecule. Polymorphisms in the protein coding part of this gene are associated with more severe pro-inflammatory responses and require supplementation for inflammatory control.
NEUROTRANSMITTER	Neurotransmitters are chemicals that are used to produce specific effects in the nervous system. These specific neurotransmitter genomics assess a person's risk for anxiety, depression and dysphoria.

COMT H62H	Catechol-O-methyltransferase (COMT) is one of several enzymes that degrade catecholamine neurotransmitters such as dopamine, epinephrine, and norepinephrine. COMT's main function is to inactivate neurotransmitters (dopamine, epinephrine, and norepinephrine) by the addition of a methyl group to the catecholamine. Normal COMT function allows people to rapidly reverse feelings of anxiety or depression. COMT (+/-) patients have sluggish ability to alter anxiety or depression episodes. COMT (+/+) patients are more prone to prolonged episodes of anxiety, depression and OCD.
COMT V158M	Catechol-O-methyltransferase (COMT) is one of several enzymes that degrade catecholamine neurotransmitters such as dopamine, epinephrine, and norepinephrine. COMT's main function is to inactivate neurotransmitters (dopamine, epinephrine, and norepinephrine) by the addition of a methyl group to the catecholamine. Normal COMT function allows people to rapidly reverse feelings of anxiety or depression. COMT (+/-) patients have sluggish ability to alter anxiety or depression episodes. COMT (+/+) patients are more prone to prolonged episodes of anxiety, depression and OCD.
GAD1	Glutamic Acid Decarboxylase (GAD 1) is the enzyme responsible for conversion of glutamic acid (a stimulant neurotransmitter) to GABA (a calming neurotransmitter). Deficiency of GABA from polymorphisms in this enzyme are associated with sleep disorders, "half glass empty" syndrome, dysphoria, and spasticity.
IL1B	Interleukin 1B is the pro-inflammatory cytokine responsible for inducing cyclooxygenase-2 (COX2) expression in the central nervous system. COX2 enzymatic function leads to prostanoid signaling that increases pain sensation associated with inflammation. Mutations in the IL1B gene are associated with many chronic inflammation disorders.
OPRM1:A118G	The OPRM1 (mu opioid receptor) is involved in pain sensitization. Polymorphisms in this gene typically are more sensitive to chronic pain and require higher doses of opioids for pain control.

Disclaimers

METHODOLOGY AND LIMITATIONS:

Testing for genetic variation/mutation on listed genes was performed using ProFlex PCR and Real-Time PCR with TaqMan® allele-specific probes on the QuantStudio 12K Flex. All genetic testing is performed by GX Sciences, 4150 Freidrich Lane, Ste H, Austin, TX. 78744. This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Test results do not rule out the possibility that this individual could be a carrier of other mutations/variations not detected by this gene mutation/variation panel. Rare mutations surrounding these alleles may also affect our detection of genetic variations. Thus, the interpretation is given as a probability. Therefore, this genetic information shall be interpreted in conjunction with other clinical findings and familial history for the administration of specific nutrients. Patients should receive appropriate genetic counseling to explain the implications of these test results. Details of assay performance and algorithms leading to clinical recommendations are available upon request. The analytical and performance characteristics of this laboratory developed test (LDT) were determined by GX Sciences' laboratory pursuant to Clinical Laboratory Improvement Amendments (CLIA) requirements.

CLIA #: 45D2144988

DISCLAIMER:

This test was developed and its performance characteristics determined by GX Sciences. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA and qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. rsIDs for the alleles being tested were obtained from the dbSNP database (Build 142).

DISCLAIMER:

UND Result: If you have received the result Variant undetermined (UND) this indicates that we were not able to determine your carrier status based on your raw data. Please refer to the GX Sciences genetic knowledge database for more information: https://www.gxsciences.com/kb_results.asp

DISCLAIMER:

Report contents and report recommendations are created and approved by GX Sciences. Sole responsibility for the proper use of the information on the GX Sciences report rests with the user, or those professionals with whom the user may consult. Nutrigenomic Testing and Neurobiologix Dietary Supplements are not "Designated Health Services" covered by Medicare or Medicaid and may not be reimbursed under any state or Federal health care program.

DISCLAIMER:

These products are not approved by the Food and Drug Administration and are not intended to diagnose, treat, cure or prevent a disease. These recommendations are for report purposes only and an individual is not required to use such products. These are recommendations only and do not replace the advisement of your own healthcare practitioner.

GX Sciences SNP References

DETOXIFICATION SNP References

ABCB1:C3435T

• Singh, A. B., Bousman, C. A., Ng, C. H., Byron, K. & Berk, M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. *Transl. Psychiatry* 2, e198 (2012). • Anton, R. F. et al. Pharmacogenomics. *Nat. Genet.* 16, 268–278 (2008). • Levran, O. et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. *Hum. Mol. Genet.* 17, 2219–2227 (2008). • De Rotte, M. C. F. J. et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. *J. Rheumatol.* 39, 2032–2040 (2012).

AHCY

• Vugrek, O., Beluži?, R. & Naki?, N. S-adenosylhomocysteine hydrolase (AHCY) deficiency: Two novel mutations with lethal outcome. *Hum. Mutat.* 30, (2009). • Motzek, A. et al. Abnormal hypermethylation at imprinting control regions in patients with S-adenosylhomocysteine hydrolase (AHCY) deficiency. *PLoS One* 11, (2016).

CTH

• Wang, J. & Hegele, R. a. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). *Hum. Genet.* 112, 404–408 (2003). • Huezio-Diaz, P. et al. Association of Cth genetic variant with veno-occlusive disease in children receiving intravenous busulfan before hematopoietic stem cell transplantation. *Blood* 120, (2012).

GSTM1

• Ghatak, S. et al. Xenobiotic Pathway Gene Polymorphisms Associated with Gastric Cancer in High Risk Mizo-Mongoloid Population, Northeast India. *Helicobacter* (2016). doi:10.1111/hel.12308 • Brackett, J. et al. Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: A report from the Childhood Cancer Survivor Study. *Neuro. Oncol.* (2012). doi:10.1093/neuonc/nos123 • Gori?ar, K. et al. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma. *Cancer Epidemiol.* (2015). doi:10.1016/j.canep.2014.12.009 • Klen, J., Gori?ar, K., Janež, A. & Dolžan, V. Common polymorphisms in antioxidant genes are associated with diabetic nephropathy in Type 2 diabetes patients. *Per. Med.* (2015). doi:10.2217/pme.14.86

GSTM3

• Maes, O. C., Schipper, H. M., Chong, G., Chertkow, H. M. & Wang, E. A GSTM3 polymorphism associated with an etiopathogenetic mechanism in Alzheimer disease. *Neurobiol. Aging* (2010). doi:10.1016/j.neurobiolaging.2008.03.007 • Patskovsky, Y. V., Huang, M. Q., Takayama, T., Listowsky, I. & Pearson, W. R. Distinctive structure of the human GSTM3 gene-inverted orientation relative to the mu class glutathione transferase gene cluster. *Arch. Biochem. Biophys.* (1999). doi:10.1006/abbi.1998.0964

GSTP1

• Sekine, I., Minna, J. D., Nishio, K., Tamura, T. & Saijo, N. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. *J Thorac Oncol* (2006). doi:01243894-200601000-00008 [pii] • Gerhard, D. S. et al. The status, quality, and expansion of the NIH full-length cDNA project: The Mammalian Gene Collection (MGC). *Genome Res.* (2004). doi:10.1101/gr.2596504 • Strange, R. C. & Fryer, A. A. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. *IARC Sci. Publ.* (1999). • Kellen, E. et al. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: A HuGE-GSEC review. *American Journal of Epidemiology* (2007). doi:10.1093/aje/kwm003 • Buch, S. C., Notani, P. N. & Bhisey, R. A. Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. *Carcinogenesis* (2002). doi:10.1093/carcin/23.5.803

INFLAMMATORY SNP References

C3

• Li, Y., Li, C. & Gao, J. Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis. *Meta Gene* (2016). doi:10.1016/j.mgene.2016.04.004 • Rasheed, H. et al. Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. *Rheumatol. (United Kingdom)* (2016). doi:10.1093/rheumatology/kew057 • Bonyadi, M. et al. Association of polymorphisms in complement component 3 with age-related macular degeneration in an Iranian population. *Ophthalmic Genet.* (2016). doi:10.3109/13816810.2015.1126612 • Nsaiba, M. J. et al. C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients. *Neurochem. Res.* (2015). doi:10.1007/s11064-015-1543-z • Prechl, J. et al. Serological and genetic evidence for altered complement system functionality in systemic lupus erythematosus: Findings of the GAPAI consortium. *PLoS One* (2016). doi:10.1371/journal.pone.0150685 • Wu, Y. et al. Interactions of environmental factors and APOA1-APOC3-APOA4-APOA5 gene cluster gene polymorphisms with metabolic syndrome. *PLoS One* (2016). doi:10.1371/journal.pone.0147946 • Saksens, N. T. M. et al. Rare Genetic Variants Associated With Development of Age-Related Macular Degeneration. *JAMA Ophthalmol.* (2016). doi:10.1001/jamaophthalmol.2015.5592 • Wu, W. et al. Polymorphisms in complement genes and risk of preeclampsia in Taiyuan, China. *Inflamm. Res.* (2016). doi:10.1007/s00011-016-0968-4

CD14

• Zhang, A. Q. et al. Association between CD14 promoter -159C/T polymorphism and the risk of sepsis and mortality: a systematic review and meta-analysis. *PLoS one* (2013). doi:10.1371/journal.pone.0071237 • Loo, W. T. Y. et al. Clinical application of human ?-defensin and CD14 gene polymorphism in evaluating the status of chronic inflammation. *J. Transl. Med.* (2012). doi:10.1186/1479-5876-10-S1-S9 • Misra, S. et al. Genetic association between inflammatory genes (IL-1?, CD14, LGALS2, PSMA6) and risk of ischemic stroke: A meta-analysis. *Meta Gene* (2016). doi:10.1016/j.mgene.2016.01.003 • Areeshi, M. Y., Mandal, R. K., Panda, A. K., Bisht, S. C. & Haque, S. CD14 -159 C>T Gene Polymorphism with Increased Risk of Tuberculosis: Evidence from a Meta-Analysis. *PLoS One* (2013). doi:10.1371/journal.pone.0064747 • Kim, E. J. et al. Helicobacter pylori infection enhances gastric mucosal inflammation in individuals carrying the 260-T allele of the CD14 gene. *Gut Liver* (2013). doi:10.5009/gnl.2013.7.3.317 • Wang, J. et al. Association between CD14 gene polymorphisms and cancer risk: A meta-analysis. *PLoS One* (2014). doi:10.1371/journal.pone.0100122 • Wang, S. et al. Racial differences in the association of CD14 polymorphisms with serum total IgE levels and allergen skin test reactivity. *J. Asthma Allergy* (2013). doi:10.2147/JAA.S42695 • Wang, Z., Hu, J., Fan, R., Zhou, J. & Zhong, J. Association between CD14 Gene C-260T Polymorphism and Inflammatory Bowel Disease: A Meta-Analysis. *PLoS One* (2012). doi:10.1371/journal.pone.0045144 • Cheah, M. T. et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. *Proc. Natl. Acad. Sci.* (2015). doi:10.1073/pnas.1424795112 • Liu, B. et al. CD14 ++ CD16 + Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell Responses. *J. Immunol.* (2015). doi:10.4049/jimmunol.1402409

CTLA4

• Patel, H. et al. Association of Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Thyroglobulin (TG) genetic variants with autoimmune hypothyroidism. *PLoS One* (2016). doi:10.1371/journal.pone.0149441 • Liu, J. & Zhang, H.-X. CTLA-4 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis. *Genet. Test. Mol. Biomarkers* (2013). doi:10.1089/gtmb.2012.0302 • Orr?, S. et al. Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia. *Hum. Immunol.* (2012). doi:10.1016/j.humimm.2011.12.014 • Wang, D. C., Tan, B. Y., Wang, F. & Yuan, Z. N. Association between CTLA-4 gene polymorphism and ankylosing spondylitis: A case-control study. *Int. J. Clin. Exp. Pathol.* (2015). • Jeffery, L. E. et al. Vitamin D antagonises the suppressive effect of inflammatory cytokines on CTLA-4 expression and regulatory function. *PLoS One* (2015). doi:10.1371/journal.pone.0131539 • Bour-Jordan, H. et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. *Immunol. Rev.* (2011). doi:10.1111/j.1600-065X.2011.01011.x • Tector, M., Khatri, B. O., Kozinski, K., Dennert, K. & Oaks, M. K. Biochemical analysis of CTLA-4 immunoreactive material from human blood.

BMC Immunol. (2009). doi:10.1186/1471-2172-10-51 • Karabon, L. et al. The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology (2009). doi:10.1111/j.1365-2567.2009.03083.x • Alfadhli, S. Overexpression and Secretion of the Soluble CTLA-4 Splice Variant in Various Autoimmune Diseases and in Cases with Overlapping Autoimmunity. Genet. Test. Mol. Biomarkers (2013). doi:10.1089/gtmb.2012.0391 • Wolff, A. S. B. et al. CTLA-4 as a genetic determinant in autoimmune Addison's disease. Genes Immun. (2015). doi:10.1038/gene.2015.27 • Zaletel, K. et al. Association of CT60 cytotoxic T lymphocyte antigen-4 gene polymorphism with thyroid autoantibody production in patients with Hashimoto's and postpartum thyroiditis. Clin. Exp. Immunol. (2010). doi:10.1111/j.1365-2249.2010.04113.x • Abdel Galil, S. M. & Hagrass, H. A. The role of CTLA-4 exon-1 49 A/G polymorphism and soluble CTLA-4 protein level in Egyptian patients with Behçet's disease. Biomed Res. Int. (2014). doi:10.1155/2014/513915 • Du, L. et al. The associations between the polymorphisms in the CTLA-4 gene and the risk of Graves' disease in the Chinese population. BMC Med. Genet. (2013). doi:10.1186/1471-2350-14-46 • Esposito, L. et al. Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles. J. Immunol. (2014). doi:10.4049/jimmunol.1303389 • Walker, L. S. K. Treg and CTLA-4: Two intertwining pathways to immune tolerance. Journal of Autoimmunity (2013). doi:10.1016/j.jaut.2013.06.006 • Zhao, J. J., Wang, D., Yao, H., Sun, D. W. & Li, H. Y. CTLA-4 and MDR1 polymorphisms increase the risk for ulcerative colitis: A meta-analysis. World J. Gastroenterol. (2015). doi:10.3748/wjg.v21.i34.10025 • Nie, W., Chen, J., Xiu, Q. Cytotoxic T-lymphocyte associated antigen 4 polymorphisms and asthma risk: A meta-analysis. PLoS One (2012). doi:10.1371/journal.pone.0042062 • Wang, J. et al. Common variants on cytotoxic T lymphocyte antigen-4 polymorphisms contributes to type 1 diabetes susceptibility: Evidence based on 58 studies. PLoS One (2014). doi:10.1371/journal.pone.0085982 • Yan, Q., Chen, P., Lu, A., Zhao, P. & Gu, A. Association between CTLA-4 60G/A and -1661A/G polymorphisms and the risk of cancers: A meta-analysis. PLoS One (2013). doi:10.1371/journal.pone.0083710

DRD2

• Clarke, T. K. et al. The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann. Hum. Genet. (2014). doi:10.1111/ahg.12046 • Anton, R. F. et al. Pharmacogenomics. Nat. Genet. (2008). doi:10.1016/j.ejca.2015.06.122 • Sasabe, T., Furukawa, A., Matsusita, S., Higuchi, S. & Ishiura, S. Association analysis of the dopamine receptor D2 (DRD2) SNP rs1076560 in alcoholic patients. Neurosci. Lett. (2007). doi:10.1016/j.neulet.2006.10.064

IL-13

• Blanchard, C. Molecular pathogenesis of eosinophilic esophagitis. Curr. Opin. Gastroenterol. (2015). doi:10.1097/MOG.000000000000186 • Seyfizadeh, N. et al. Association of IL-13 single nucleotide polymorphisms in Iranian patients to multiple sclerosis. Am. J. Clin. Exp. Immunol. (2014). • Egli, A. et al. IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza. PLoS Pathog. (2014). doi:10.1371/journal.ppat.1004556 • Liu, Z. et al. A meta-analysis of IL-13 polymorphisms and pediatric asthma risk. Medical science monitor : international medical journal of experimental and clinical research. (2014). Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25502839>. • Cianferoni, A. & Spergel, J. M. From genetics to treatment of eosinophilic esophagitis. Current Opinion in Allergy and Clinical Immunology (2015). doi:10.1097/ACI.0000000000000200 • Narozna, B. et al. Polymorphisms in the interleukin 4, interleukin 4 receptor and interleukin 13 genes and allergic phenotype: A case control study. Adv. Med. Sci. (2016). doi:10.1016/j.adms.2015.07.003 • Shamran, H. A. et al. Single nucleotide polymorphisms in IL-10, IL-12p40, and IL-13 genes and susceptibility to glioma. Int. J. Med. Sci. (2015). doi:10.7150/ijms.12609 • Mitchel, J. A. et al. IL-13 Augments Compressive Stress-Induced Tissue Factor Expression in Human Airway Epithelial Cells. Am. J. Respir. Cell Mol. Biol. (2016). doi:10.1165/rcmb.2015-0252OC • Nicodemus-Johnson, J. et al. Genome-wide methylation study identifies an IL-13-induced epigenetic signature in asthmatic airways. Am. J. Respir. Crit. Care Med. (2016). doi:10.1164/rccm.201506-1243OC • Chen, P., Chen, C., Chen, K., Xu, T. & Luo, C. Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis. Tumor Biology (2014). doi:10.1007/s13277-014-2895-8 • Accordini, S. et al. An Interleukin 13 polymorphism is associated with symptom severity in adult subjects with ever asthma. PLoS One (2016). doi:10.1371/journal.pone.0151292 • Sonntag, K. et al. Chronic graft-versus-host-disease in CD34+ humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. J. Autoimmun. (2015). doi:10.1016/j.jaut.2015.06.006 • McCormick, S. M. & Heller, N. M. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine (2015). doi:10.1016/j.cyt.2015.05.023 • Gervas-Arruga, J. et al. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease. PLoS One (2015). doi:10.1371/journal.pone.0126153

IL-5

• Burnham, M. E. et al. Cholesterol selectively regulates IL-5 induced mitogen activated protein kinase signaling in human eosinophils. PLoS One (2014). doi:10.1371/journal.pone.0103122 • Skrindo, I. et al. IL-5 production by resident mucosal allergen-specific T cells in an explant model of allergic rhinitis. Clin. Exp. Allergy (2015). doi:10.1111/cea.12543 • Turkeli, A. et al. IL-5, IL-8 and MMP -9 levels in exhaled breath condensate of atopic and nonatopic asthmatic children. Respiratory medicine. (2015). Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25937050>. • Bafadhel, M. et al. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration (2009). doi:10.1159/000221902 • Molino, N. A., Gossage, D., Kolbeck, R., Parker, J. M. & Geba, G. P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clinical and Experimental Allergy (2012). doi:10.1111/j.1365-2222.2011.03854.x • Corren, J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov. Med. (2012). • Schulten, V. et al. Previously undescribed grass pollen antigens are the major inducers of T helper 2 cytokine-producing T cells in allergic individuals. Proc. Natl. Acad. Sci. (2013). doi:10.1073/pnas.1300512110 • Larose, M. C. et al. Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol. Journal of Allergy and Clinical Immunology (2014). doi:10.1016/j.jaci.2013.12.1081 • Weber-Chrysochoou, C., Crisafulli, D., Kemp, A. S., Britton, W. J. & Marks, G. B. Allergen-specific IL-5 responses in early childhood predict asthma at age eight. PLoS One (2014). doi:10.1371/journal.pone.0097995 • Silveira, A. et al. Plasma IL-5 concentration and subclinical carotid atherosclerosis. Atherosclerosis (2015). doi:10.1016/j.atherosclerosis.2014.12.046

IL6

• Anton, R. F. et al. Pharmacogenomics. Nat. Genet. (2008). doi:10.1016/j.ejca.2015.06.122 • Fishman, D. et al. The effect of novel polymorphisms in the interleukin-6 (IL6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. (1998). doi:10.1172/JCI2629 • Ilig, T. et al. Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. J. Clin. Endocrinol. Metab. (2004). doi:10.1210/jc.2004-0355 • Baumert, P., Lake, M. J., Stewart, C. E., Drust, B. & Erskine, R. M. Genetic variation and exercise-induced muscle damage: implications for athletic performance, injury and ageing. European Journal of Applied Physiology (2016). doi:10.1007/s00421-016-3411-1 • Buxens, A. et al. Can we predict top-level sports performance in power vs endurance events? A genetic approach. Scand. J. Med. Sci. Sport. (2011). doi:10.1111/j.1600-0838.2009.01079.x

STAT4

• Glas, J. et al. Evidence for STAT4 as a common autoimmune gene: Rs7574865 is associated with colonic Crohn's disease and early disease onset. PLoS One (2010). doi:10.1371/journal.pone.0010373 • Sigurdsson, S. et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum. Mol. Genet. (2008). doi:10.1093/hmg/ddn184 • Namjou, B. et al. High-density genotyping of STAT4 reveals multiple haplotypic associations with Systemic lupus erythematosus in different racial groups. Arthritis Rheum. (2009). doi:10.1002/art.24387 • Sugiura, T. et al. Association between a C8orf13-BLK polymorphism and polymyositis/dermatomyositis in the Japanese population: An additive effect with STAT4 on disease susceptibility. PLoS One (2014). doi:10.1371/journal.pone.0090019 • Gourh, P. et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: Evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum. (2009). doi:10.1002/art.24958 • Lamana, A. et al. The T1 genotype of the STAT4 rs7574865 polymorphism is associated with high disease activity and disability in patients with early arthritis. PLoS One (2012). doi:10.1371/journal.pone.0043661 • Yan, N. et al. Association between STAT4 Gene Polymorphisms and Autoimmune Thyroid Diseases in a Chinese Population. Int. J. Mol. Sci. (2014). doi:10.3390/ijms150712280 • Svensson, A. et al. STAT4 Regulates Antiviral Gamma Interferon Responses and Recurrent Disease during Herpes Simplex Virus 2 Infection. J. Virol. (2012). doi:10.1128/JVI.00947-12 • Wang, Y., Qu, A. & Qu, A. Signal transducer and activator of transcription 4 in liver diseases. International Journal of Biological Sciences (2015). doi:10.7150/ijbs.11164 • Lamana, A. et al. The minor allele of rs7574865 in the STAT4 gene is associated with increased mRNA and protein expression. PLoS One (2015). doi:10.1371/journal.pone.0142683 • McWilliams, I. L., Rajbhandari, R., Nozell, S., Benveniste, E. & Harrington, L. E. STAT4 controls GM-CSF production by both Th1 and Th17 cells during EAE. J. Neuroinflammation (2015). doi:10.1186/s12974-015-0351-3 • Jabeen, R. et al. Altered STAT4 Isoform Expression in Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. (2015). doi:10.1097/MIB.0000000000000495

TNF

• Laddha, N. C., Dwivedi, M., Gani, A. R., Mansuri, M. S. & Begum, R. Tumor Necrosis Factor B (TNFB) genetic variants and its increased expression are associated with vitiligo susceptibility. PLoS One (2013). doi:10.1371/journal.pone.0081736 • Yang, J.-K., Wu, W.-J., Qi, J., He, L. & Zhang, Y.-P. TNF -308 G/A Polymorphism and Risk of Acne Vulgaris: A Meta-Analysis. PLoS ONE 9, (2014). • Delongui, F. et al. Association of tumor necrosis factor β genetic polymorphism and sepsis susceptibility. Exp. Ther. Med. (2011). doi:10.3892/etm.2011.213 • Feng, R. N., Zhao, C., Sun, C. H. & Li, Y. Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS One (2011). doi:10.1371/journal.pone.0018480 • Khan, S. et al. TNF-? -308 G?>-7A (rs1800629) Polymorphism is Associated with Celiac Disease: A Meta-analysis of 11 Case-Control Studies. Scientific Reports 6, (2016). • Li, H. H. et al. Tumor Necrosis Factor-? Gene Polymorphism Is Associated with Metastasis in Patients with Triple Negative Breast Cancer. Sci. Rep. (2015). doi:10.1038/srep10244 • Ayhan, G. et al. Relation between inflammatory cytokine levels in serum and bronchoalveolar lavage fluid and gene polymorphism in young adult patients with bronchiectasis. J. Thorac. Dis. (2014). doi:10.3978/j.issn.2072-1439.2014.04.14 • Chen, S. et al. Associations between TNF-?308A/G Polymorphism and Susceptibility with Dermatomyositis: A Meta-Analysis. PLoS ONE 9, (2014). • Chen, M. et al. Tumor Necrosis Factor (TNF) -308G>A, Nitric Oxide Synthase 3 (NOS3) +894G>T polymorphisms and migraine risk: A meta-analysis. PLoS One (2015). doi:10.1371/journal.pone.0129372 • Lee, J. et al. Genetic polymorphism at codon 10 of the transforming growth factor-?1 gene in patients with alcoholic liver cirrhosis. Korean J. Hepatol. (2011). doi:10.3350/kjhep.2011.17.1.37 • Zeng, X., Zhang, L., Gu, H. & Gu, Y. Association between TNF-? -308 G/A polymorphism and COPD susceptibility: a meta-analysis update. International Journal of Chronic Obstructive Pulmonary Disease 1367 (2016). doi:10.2147/copd.s105394 • Li, M., Han, Y., Wu, T. T., Feng, Y. & Wang, H. B. Tumor Necrosis Factor Alpha rs1800629 Polymorphism and Risk of Cervical Lesions: A Meta-Analysis. PLoS One (2013). doi:10.1371/journal.pone.0069201 • Guo, X. F. et al. TNF-?308 polymorphism and risk of digestive system cancers: A meta-analysis. World J. Gastroenterol. (2013). doi:10.3748/wjg.v19.i48.9461 • Ma, Zhang & Baloch. Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-? (TNF-?) in Major Depressive Disorder: A Systematic Review. Int. J. Mol. Sci. (2016). doi:10.1016/j.cherd.2012.09.019

NEUROTRANSMITTER SNP References

COMT

• Bonifácio, M. J., Palma, P. N., Almeida, L. & Soares-Da-Silva, P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Reviews (2007). doi:10.1111/j.1527-3458.2007.00020.x • Axelrod, J. O-methylation of epinephrine and other catechols in vitro and in vivo. Science (80-.). (1957). doi:10.1126/science.126.3270.400 • Ulmanen, I. et al. Expression and intracellular localization of catechol O-methyltransferase in transfected mammalian cells. Eur. J. Biochem. (1997). doi:10.1111/j.1432-1033.1997.0452a.x • Stein, M. B., Fallin, M. D., Schork, N. J. & Gelernter, J. COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology (2005). doi:10.1038/sj.npp.1300787 • Lotta, T. et al. Kinetics of Human Soluble and Membrane-Bound Catechol O-Methyltransferase: A Revised Mechanism and Description of the Thermolabile Variant of the Enzyme. Biochemistry (1995). doi:10.1021/bi00013a008 • Grossman, M. H., Emanuel, B. S. & Budarf, M. L. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1.2. Genomics (1992). doi:10.1016/0888-7543(92)90316-K • Golan, D. E., Armstrong, E. J. & Armstrong, A. W. Principles of pharmacology: the pathophysiologic basis of drug therapy. (Wolters Kluwer Health, 2017).

• Wichers, M. et al. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. *Neuropsychopharmacology* (2008). doi:10.1038/sj.npp.1301520 • Diamond, A., Briand, L., Fossella, J. & Gehlbach, L. Genetic and Neurochemical Modulation of Prefrontal Cognitive Functions in Children. *Am. J. Psychiatry* (2004). doi:10.1176/appi.ajp.161.1.125 • Robinson, S., Goddard, L., Dritschel, B., Wisley, M. & Howlin, P. Executive functions in children with Autism Spectrum Disorders. *Brain Cogn.* (2009). doi:10.1016/j.bandc.2009.06.007 • Bruder, G. E. et al. Catechol-O-methyltransferase (COMT) genotypes and working memory: Associations with differing cognitive operations. *Biol. Psychiatry* (2005). doi:10.1016/j.biopsych.2005.05.010 • Chen, J. et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. *Am. J. Hum. Genet.* (2004). doi:10.1086/425589 • Tai, C. H. & Wu, R. M. Catechol-O-methyltransferase and Parkinson's disease. *Acta Medica Okayama* (2002).

GAD1

• Bu, D. F. & Tobin, A. J. The exon-intron organization of the genes (*gad1* and *gad2*) encoding two human glutamate decarboxylases (*gad67* and *gad65*) suggests that they derive from a common ancestral *gad*. *Genomics* (1994). doi:10.1006/geno.1994.1246 • Dirix, R. et al. Targeting of the 67-kDa isoform of glutamic acid decarboxylase to intracellular organelles is mediated by its interaction with the NH₂-terminal region of the 65-kDa isoform of glutamic acid decarboxylase. *J. Biol. Chem.* (1995). doi:10.1074/jbc.270.5.2241 • Giorda, R., Peakman, M., Tan, K. C., Vergani, D. & Trucco, M. Glutamic acid decarboxylase expression in islets and brain. *The Lancet* (1991). doi:10.1016/0140-6736(91)92781-V • KELLY, C. D. et al. Nucleotide sequence and chromosomal assignment of a cDNA encoding the large isoform of human glutamate decarboxylase. *Ann. Hum. Genet.* (1992). doi:10.1111/j.1469-1809.1992.tb01150.x • Demakova, E. V., Korobov, V. P. & Lemkina, L. M. Determination of gamma-aminobutyric acid concentration and activity of glutamate decarboxylase in blood serum of patients with multiple sclerosis. *Klin. Lab. Diagn.* (2003). • Asada, H. et al. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. *Biochem. Biophys. Res. Commun.* (1996). doi:10.1006/bbrc.1996.1898 • McHale, D. P. et al. A Gene for Autosomal Recessive Symmetrical Spastic Cerebral Palsy Maps to Chromosome 2q24-25. *Am. J. Hum. Genet.* (1999). doi:10.1086/302237

IL1B

• Anton, R. F. et al. Pharmacogenomics. *Nat. Genet.* (2008). doi:10.1016/j.ejca.2015.06.122 • Licastro, F. et al. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. *Ann. Neurol.* (2000). doi:3.0.CO;2-G • Carter, K. W. et al. Association of Interleukin-1 gene polymorphisms with central obesity and metabolic syndrome in a coronary heart disease population. *Hum. Genet.* (2008). doi:10.1007/s00439-008-0540-6

OPRM1:A118G

• Veluchamy, A., Hébert, H. L., Meng, W., Palmer, C. N. A. & Smith, B. H. A systematic review and meta-analysis of genetic risk factors for neuropathic pain. *Pain* 1 (2018). doi:10.1097/j.pain.0000000000001164 • Anton, R. F. et al. An Evaluation of the μ -Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence. *Arch. Gen. Psychiatry* 65, 135 (2008). • van den Wildenberg, E. et al. A Functional Polymorphism of the μ -Opioid Receptor Gene (OPRM1) Influences Cue-Induced Craving for Alcohol in Male Heavy Drinkers. *Alcohol. Clin. Exp. Res.* 31, 1–10 (2007). • Haerian, B. S. & Haerian, M. S. OPRM1 rs179971 polymorphism and opioid dependence: evidence from a meta-analysis. *Pharmacogenomics* 14, 813–824 (2013). • Bjorland, S., Moen, A., Schistad, E., Gjerstad, J. & Roe, C. Genes associated with persistent lumbar radicular pain; a systematic review. *BMC Musculoskelet. Disord.* 17, 500 (2016).